Altered dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil containing chemotherapy

Nucleosides, Nucleotides and Nucleic Acids

Volumn 27, Issue 6-7, 2008, Pages 726-732

  Van Kuilenburg, André B P ^a,c   Klumpen, Heinz Josef ^a   Westermann, Anneke M ^a   Zoetekouw, Lida ^a   Bakker, Piet J M ^a   Guchelaar, Henk Jan ^b   Richel, Dick J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil; Dihydropyrimidine dehydrogenase; FBAL; Fluoro 5; 6 dihydrouracil; Toxicity

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; LAPATINIB; OXALIPLATIN;

ADULT; AGED; BILE DUCT CANCER; BREAST CANCER; CLINICAL ARTICLE; COLON CANCER; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ESOPHAGUS CANCER; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; MALE; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL BLOOD MONONUCLEAR CELL; PROGNOSIS; RISK FACTOR; SKIN TOXICITY; STOMACH CANCER; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HEMATOLOGY; HUMANS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 46749092011     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257770802145454     Document Type: Conference Paper

References (23)

1. Meyerhardt, J.A.; Mayer, R.J. Systemic therapy for colorectal cancer. N. Engl. J. Med. 2005, 352, 476-487.
2. Twelves, C.; Wong, A.; Nowacki, M.P.; Abt, M.; Burris, H.; III; Carrato, A.; Cassidy, J.; Cervantes, A.; Fagerberg, J.; Georgoulias, V.; Husseini, F.; Jodrell, D.; Koralewski, P.; Kroning, H.; Maroun, J.; Marschner, N.; McKendrick, J.; Pawlicki, M.; Rosso, R.; Schuller, J.; Seitz, J.F.; Stabuc, B.; Tujakowski, J.; Van Hazel, G.; Zaluski, J.; Scheithauer, W. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med. 2005, 352, 2696-2704.
3. Andre, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I.; de Gramont, A. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med. 2004, 350, 2343-2351.
4. Douillard, J.Y.; Cunningham, D.; Roth, A.D.; Navarro, M.; James, R.D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355, 1041-1047.
5. Mattison, L.K.; Soong, R.; Diasio, R.B. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2002, 3, 485-492.
6. van Kuilenburg, A.B.P. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer. 2004, 40, 939-950.
7. Diasio, R.B.; Beavers, T.L.; Carpenter, J.T. Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J. Clin. Invest. 1988, 81, 47-51.
8. Maring, J.G.; van Kuilenburg, A.B.P.; Haasjes, J.; Piersma, H.; Groen, H.J.M.; Uges, D.R.A.; van Gennip, A.H.; de Vries, E.G.E. Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br. J. Cancer. 2002, 86, 1028-1033.
9. Milano, G.A.; Etienne, M.C.; Pierrefite, V.; Barberi-Heyob, M.; Deporte-Fety, R.; Renée, N. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity. Br. J. Cancer. 1999, 79, 627-630.
10. van Kuilenburg, A.B.P.; Haasjes, J.; Richel, D.J.; Zoetekouw, L.; van Lenthe, H.; De Abreu, R.A.; Maring, J.G.; Vreken, P.; van Gennip, A.H. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin. Cancer Res. 2000, 6, 4705-4712.
11. Johnson, M.R.; Diasio, R.B. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv. Enzyme Regul. 2002, 41, 151-157.
12. van Kuilenburg, A.B.P.; van Lenthe, H.; Tromp, A.; Veltman, P.C.J.; van Gennip, A.H. Pitfalls in the diagnosis of patients with a partial dihydropyrimidine dehydrogenase deficiency. Clin. Chem. 2000, 46, 9-17.
13. Smith, P.K.; Krohn, R.I.; Hermanson, G.T.; Mallia, A.K.; Gartner, F.H.; Provenzano, M.D.; Fujimoto, E.K.; Goeke, N.M.; Olson, B.J.; Klenk, D.C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 1985, 150, 76-85.
14. van Kuilenburg, A.B.P.; Meinsma, J.R.; Zoetekouw, L.; van Gennip, A.H. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int. J. Cancer. 2002, 101, 253-258.
15. van Kuilenburg, A.B.P.; Klumpen, H.J.; Westermann, A.M.; Zoetekouw, L.; van, Lenthe, H.; Bakker, P.J.; Richel, D.J.; Guchelaar, H.J. Increased dihydropyrimidine dehydrogenase activity associated with mild toxicity in patients treated with 5-fluorouracil and leucovorin. Eur. J. Cancer. 2007, 43, 459-465.
16. van Kuilenburg, A.B.P.; Meinsma, J.R.; Zonnenberg, B.A.; Zoetekouw, L.; Baas, F.; Matsuda, K.; Tamaki, N.; van Gennip, A.H. Dihydropyrimidinase deficiency and severe 5-Fluorouracil toxicity. Clin. Cancer Res. 2003, 9, 4363-4367.
17. Spector, T.; Cao, S.; Rustum, Y.M.; Harrington, J.A.; Porter, D.J.T. Attenuation of the antitumor activity of 5-fluorouracil by (R)-5-fluoro-5,6- dihydrouracil. Cancer Res. 1995, 55, 1239-1241.
18. Cao, S.; Baccanari, D.P.; Rustum, Y.M.; Davis, S.T.; Tansik, R.L.; Porter, D.J.T.; Spector, T. alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil. Biochem. Pharmacol. 2000, 59, 953-960.
19. alpha-fluoro-beta-alanine: effects on the antitumor activity and toxicity of 5-fluorouracil. Biochem. Pharmacol. 2000, 59, 953-960.
20. Gieschke, R.; Burger, H.U.; Reigner, B.; Blesch, K.S.; Steimer, J.L. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. Br. J. Clin. Pharmacol. 2003, 55, 252-263.
21. Burris, H.A.; III, Hurwitz, H.I.; Dees, E.C.; Dowlati, A.; Blackwell, K.L.; O'Neil, B.; Marcom, P.K.; Ellis, M.J.; Overmoyer, B.; Jones, S.F.; Harris, J.L.; Smith, D.A.; Koch, K.M.; Stead, A.; Mangum, S.; Spector, N.L.P. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 2005, 23, 5305-5313.
22. Douillard, J.Y.; Hoff, P.M.; Skillings, J.R.; Eisenberg, P.; Davidson, N.; Harper, P.; Vincent, M.D.; Lembersky, B.C.; Thompson, S.; Maniero, A.; Benner, S.E. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 2002, 20, 3605-3616.
23. Cassidy, J.; Twelves, C.; Van, C.E.; Hoff, P.; Bajetta, E.; Boyer, M.; Bugat, R.; Burger, U.; Garin, A.; Graeven, U.; McKendric, J.; Maroun, J.; Marshall, J.; Osterwalder, B.; Perez-Manga, G.; Rosso, R.; Rougier, P.; Schilsky, R.L. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann. Oncol. 2002, 13, 566-575.